Mumbai: Amneal Pharmaceuticals, the third largest generic drugmaker in the US, plans to invest $150-200 million over the next four to five years to build a manufacturing facility in Ahmedabad housing two greenfield plants for producing weight loss drugs.
The project will also feature investments from US biotech firm Metsera in addition to fiscal incentives from the Gujarat government.
"So, the total project size could reach up to $250 million to $300 million in the next four to five years," Chirag Patel, president and co-CEO told ET.
One of the plants will be used for producing peptide synthesis, and the other for sterile fill-finish manufacturing. The new site broke ground on Tuesday.
"Phase one is 100 million capacity, and up to five tons of API...(our) preference is Metsara, obviously innovative side along with providing some capacity to the big guys like Novo Nordisk and Eli Lilly, right, and we will have our generic portfolio including generic GLP-1 going forward," Patel said.
Additionally, Amneal will support Metsera with certain product development activities, including drug substance manufacturing, product formulation and drug-device development. Patel added that locating the proposed facility in India allows Amneal to benefit from the country's skilled workforce and competitive manufacturing costs.
The project will also feature investments from US biotech firm Metsera in addition to fiscal incentives from the Gujarat government.
"So, the total project size could reach up to $250 million to $300 million in the next four to five years," Chirag Patel, president and co-CEO told ET.
One of the plants will be used for producing peptide synthesis, and the other for sterile fill-finish manufacturing. The new site broke ground on Tuesday.
"Phase one is 100 million capacity, and up to five tons of API...(our) preference is Metsara, obviously innovative side along with providing some capacity to the big guys like Novo Nordisk and Eli Lilly, right, and we will have our generic portfolio including generic GLP-1 going forward," Patel said.
Additionally, Amneal will support Metsera with certain product development activities, including drug substance manufacturing, product formulation and drug-device development. Patel added that locating the proposed facility in India allows Amneal to benefit from the country's skilled workforce and competitive manufacturing costs.
You may also like
Bodybuilder found dead at gym after lying under cold shower for 15 hours
ITV Big Brother's 'harsh' task sparks confusion among viewers
Great British Bake Off drama as contestant walks away in tears when bake goes horribly wrong
Cole Palmer wins huge England award as Jude Bellingham and Harry Kane snubbed
